RxDoctor Payments DataLook up a doctor →

Harold Farber, MD

Dermatology · Philadelphia, PANPI 1194833590

Payments from drug & device makers

$284,076in general payments, 2019–2025

Across 857 payments — averaging $331.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$65K
  • Dermavant Sciences, Inc.$41K
  • Arcutis Biotherapeutics, Inc.$32K
  • Organon$25K
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$21K
  • Almirall LLC$21K
  • plus $79K from 40 others

What the payments were for

  • Consulting fees$57,30520%
  • Speaking & faculty fees$190,22067%
  • Travel & lodging$14,0635%
  • Food & beverage$22,3888%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$284,076 in reported general payments places this provider in the 95th percentile of 626 dermatology providers in Pennsylvania.

See all dermatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,648,355
Medicare patients
486
Services billed
17,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab14$89,426
ZoryveRoflumilast48$40,076
VtamaTapinarof14$18,969
Ketoconazole122$6,097
Clocortolone Pivalate11$3,420
Clindamycin Phosphate54$2,541
Triamcinolone Acetonide177$1,977
Mupirocin256$1,818
Hydrocortisone79$1,498
Mometasone Furoate79$1,405
Metronidazole15$1,198
Calcipotriene13$1,135
Clobetasol Propionate28$988
Gentamicin Sulfate26$944
Cephalexin42$772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Arcutis Biotherapeutics, Inc.Zoryve$31,859$40,07648 claims
Dermavant Sciences, Inc.Vtama$40,816$18,96914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 626 dermatology providers in Pennsylvania.

Other dermatology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →